Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model

J. Ai, L. E. Pascal, K. J. O'Malley, J. A. Dar, Sudhir Isharwal, Z. Qiao, B. Ren, L. H. Rigatti, R. Dhir, W. Xiao, J. B. Nelson, Z. Wang

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Multiple genetic alterations are associated with prostate carcinogenesis. Tumor-suppressor genes phosphatase and tensin homolog deleted on chromosome 10 (Pten) and androgen upregulated gene 19 (U19), which encodes ELL-associated factor 2 (EAF2), are frequently inactivated or downregulated in advanced prostate cancers. Previous studies showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice. However, EAF2-knockout mice did not develop prostate cancer even at 2 years of age. To further define the roles of EAF2 in prostate carcinogenesis, we crossed the Pten+/- and EAF2+/- mice in the C57/BL6 background to generate EAF2-/-Pten+/-, Pten+/-, EAF2-/- and wild-type mice. The prostates from virgin male mice with the above four genotypes were analyzed at 7 weeks, 19 weeks and 12 months of age. Concomitant loss of EAF2 function and inactivation of one Pten allele induced spontaneous prostate cancer in 33% of the mice. Prostatic tissues from intact EAF2-/- Pten+/- mice exhibited higher levels of phospho-Akt, -p44/42 and microvessel density. Moreover, phospho-Akt remained high after castration. Consistently, there was a synergistic increase in prostate epithelial proliferation in both intact and castrated EAF2-/-Pten+/- mice. Using laser-capture microdissection coupled with real-time reverse transcription-PCR, we confirmed that co-downregulation of EAF2 and Pten occurred in >50% clinical prostate cancer specimens with Gleason scores of 8-9 (n=11), which is associated with poor prognosis. The above findings together demonstrated synergistic functional interactions and clinical relevance of concurrent EAF2 and Pten downregulation in prostate carcinogenesis.

Original languageEnglish (US)
Pages (from-to)2286-2294
Number of pages9
JournalOncogene
Volume33
Issue number18
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

Prostate
Carcinogenesis
Prostatic Neoplasms
Down-Regulation
Genes
Prostatic Intraepithelial Neoplasia
Laser Capture Microdissection
Chromosomes, Human, Pair 10
Neoplasm Grading
Castration
Microvessels
Tumor Suppressor Genes
Phosphoric Monoester Hydrolases
Knockout Mice
Androgens
Reverse Transcription
Alleles
Genotype
Polymerase Chain Reaction
mouse FESTA protein

Keywords

  • EAF2/U19
  • Knockout
  • Prostate cancer
  • Pten

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. / Ai, J.; Pascal, L. E.; O'Malley, K. J.; Dar, J. A.; Isharwal, Sudhir; Qiao, Z.; Ren, B.; Rigatti, L. H.; Dhir, R.; Xiao, W.; Nelson, J. B.; Wang, Z.

In: Oncogene, Vol. 33, No. 18, 01.05.2014, p. 2286-2294.

Research output: Contribution to journalArticle

Ai, J, Pascal, LE, O'Malley, KJ, Dar, JA, Isharwal, S, Qiao, Z, Ren, B, Rigatti, LH, Dhir, R, Xiao, W, Nelson, JB & Wang, Z 2014, 'Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model', Oncogene, vol. 33, no. 18, pp. 2286-2294. https://doi.org/10.1038/onc.2013.190
Ai, J. ; Pascal, L. E. ; O'Malley, K. J. ; Dar, J. A. ; Isharwal, Sudhir ; Qiao, Z. ; Ren, B. ; Rigatti, L. H. ; Dhir, R. ; Xiao, W. ; Nelson, J. B. ; Wang, Z. / Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model. In: Oncogene. 2014 ; Vol. 33, No. 18. pp. 2286-2294.
@article{879f5bb2bb564503968f2f8c31b508f4,
title = "Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model",
abstract = "Multiple genetic alterations are associated with prostate carcinogenesis. Tumor-suppressor genes phosphatase and tensin homolog deleted on chromosome 10 (Pten) and androgen upregulated gene 19 (U19), which encodes ELL-associated factor 2 (EAF2), are frequently inactivated or downregulated in advanced prostate cancers. Previous studies showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice. However, EAF2-knockout mice did not develop prostate cancer even at 2 years of age. To further define the roles of EAF2 in prostate carcinogenesis, we crossed the Pten+/- and EAF2+/- mice in the C57/BL6 background to generate EAF2-/-Pten+/-, Pten+/-, EAF2-/- and wild-type mice. The prostates from virgin male mice with the above four genotypes were analyzed at 7 weeks, 19 weeks and 12 months of age. Concomitant loss of EAF2 function and inactivation of one Pten allele induced spontaneous prostate cancer in 33{\%} of the mice. Prostatic tissues from intact EAF2-/- Pten+/- mice exhibited higher levels of phospho-Akt, -p44/42 and microvessel density. Moreover, phospho-Akt remained high after castration. Consistently, there was a synergistic increase in prostate epithelial proliferation in both intact and castrated EAF2-/-Pten+/- mice. Using laser-capture microdissection coupled with real-time reverse transcription-PCR, we confirmed that co-downregulation of EAF2 and Pten occurred in >50{\%} clinical prostate cancer specimens with Gleason scores of 8-9 (n=11), which is associated with poor prognosis. The above findings together demonstrated synergistic functional interactions and clinical relevance of concurrent EAF2 and Pten downregulation in prostate carcinogenesis.",
keywords = "EAF2/U19, Knockout, Prostate cancer, Pten",
author = "J. Ai and Pascal, {L. E.} and O'Malley, {K. J.} and Dar, {J. A.} and Sudhir Isharwal and Z. Qiao and B. Ren and Rigatti, {L. H.} and R. Dhir and W. Xiao and Nelson, {J. B.} and Z. Wang",
year = "2014",
month = "5",
day = "1",
doi = "10.1038/onc.2013.190",
language = "English (US)",
volume = "33",
pages = "2286--2294",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model

AU - Ai, J.

AU - Pascal, L. E.

AU - O'Malley, K. J.

AU - Dar, J. A.

AU - Isharwal, Sudhir

AU - Qiao, Z.

AU - Ren, B.

AU - Rigatti, L. H.

AU - Dhir, R.

AU - Xiao, W.

AU - Nelson, J. B.

AU - Wang, Z.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Multiple genetic alterations are associated with prostate carcinogenesis. Tumor-suppressor genes phosphatase and tensin homolog deleted on chromosome 10 (Pten) and androgen upregulated gene 19 (U19), which encodes ELL-associated factor 2 (EAF2), are frequently inactivated or downregulated in advanced prostate cancers. Previous studies showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice. However, EAF2-knockout mice did not develop prostate cancer even at 2 years of age. To further define the roles of EAF2 in prostate carcinogenesis, we crossed the Pten+/- and EAF2+/- mice in the C57/BL6 background to generate EAF2-/-Pten+/-, Pten+/-, EAF2-/- and wild-type mice. The prostates from virgin male mice with the above four genotypes were analyzed at 7 weeks, 19 weeks and 12 months of age. Concomitant loss of EAF2 function and inactivation of one Pten allele induced spontaneous prostate cancer in 33% of the mice. Prostatic tissues from intact EAF2-/- Pten+/- mice exhibited higher levels of phospho-Akt, -p44/42 and microvessel density. Moreover, phospho-Akt remained high after castration. Consistently, there was a synergistic increase in prostate epithelial proliferation in both intact and castrated EAF2-/-Pten+/- mice. Using laser-capture microdissection coupled with real-time reverse transcription-PCR, we confirmed that co-downregulation of EAF2 and Pten occurred in >50% clinical prostate cancer specimens with Gleason scores of 8-9 (n=11), which is associated with poor prognosis. The above findings together demonstrated synergistic functional interactions and clinical relevance of concurrent EAF2 and Pten downregulation in prostate carcinogenesis.

AB - Multiple genetic alterations are associated with prostate carcinogenesis. Tumor-suppressor genes phosphatase and tensin homolog deleted on chromosome 10 (Pten) and androgen upregulated gene 19 (U19), which encodes ELL-associated factor 2 (EAF2), are frequently inactivated or downregulated in advanced prostate cancers. Previous studies showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice. However, EAF2-knockout mice did not develop prostate cancer even at 2 years of age. To further define the roles of EAF2 in prostate carcinogenesis, we crossed the Pten+/- and EAF2+/- mice in the C57/BL6 background to generate EAF2-/-Pten+/-, Pten+/-, EAF2-/- and wild-type mice. The prostates from virgin male mice with the above four genotypes were analyzed at 7 weeks, 19 weeks and 12 months of age. Concomitant loss of EAF2 function and inactivation of one Pten allele induced spontaneous prostate cancer in 33% of the mice. Prostatic tissues from intact EAF2-/- Pten+/- mice exhibited higher levels of phospho-Akt, -p44/42 and microvessel density. Moreover, phospho-Akt remained high after castration. Consistently, there was a synergistic increase in prostate epithelial proliferation in both intact and castrated EAF2-/-Pten+/- mice. Using laser-capture microdissection coupled with real-time reverse transcription-PCR, we confirmed that co-downregulation of EAF2 and Pten occurred in >50% clinical prostate cancer specimens with Gleason scores of 8-9 (n=11), which is associated with poor prognosis. The above findings together demonstrated synergistic functional interactions and clinical relevance of concurrent EAF2 and Pten downregulation in prostate carcinogenesis.

KW - EAF2/U19

KW - Knockout

KW - Prostate cancer

KW - Pten

UR - http://www.scopus.com/inward/record.url?scp=84899905173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899905173&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.190

DO - 10.1038/onc.2013.190

M3 - Article

VL - 33

SP - 2286

EP - 2294

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 18

ER -